饒 勇  共産黨員  研究員  博士/碩士生導師，365英国上市官网在线測試中心主任

  郵箱： raoyong0805@126.com

  1.教育背景

  2006.9-2010.6  湖北師範大學 生命科學學院 理學學士

   2010.9-2013.6  廣東醫科大學 基礎醫學院 醫學碩士

   2013.9-2016.6 中山大學 365英国上市官网在线 理學博士

   2016.7-2021.7 中山大學 365英国上市官网在线 副研究員

   2021.8起    365英国上市官网在线 研究員

  2. 科研情況

主持項目6項，包括國家自然科學基金青年項目、國家自然科學基金地區基金項目、海南省自然科學基金面上項目等。以項目第一參與人參與科研項目總經費約900萬，包括國家自然科學基金重點項目、面上項目、廣州市民生科技重大專項等。已發表SCI論文20多篇，其中一作/通訊（含）論文18篇，中科院一區論文14篇；申請/授權專利6項，PCT專利3項。

3. 研究領域

慢性脂肪性肝病與神經退行性疾病分子藥理學與創新藥物研究；

線粒體代謝調控分子藥理學研究；

4. 社會兼職

擔任J Med Chem, Eur J Med Chem, Brit J Pharmacol，Gut Microbes等期刊審稿人

5. 代表性項目

1）國家自然科學基金地區基金， NASH治療新靶點ASNS蛋白抑制劑設計合成及其增強肝髒線粒體代謝活性研究，主持

2）國家自然科學基金青年基金，抗非酒精性脂肪性肝炎（NASH）新型先導化合物發現及作用機制研究，主持

3）海南省自然科學基金面上項目，阿片類藥物Flupirtine maleate靶向抑制ASNS蛋白調控肝髒糖脂代謝抗MAFLD研究，主持

4）廣東省自然科學基金面上項目，新型HSP90抑制劑的設計合成及其調控能量代謝抗非酒精性脂肪性肝炎活性與新機制研究，主持

5）中山大學青年培育項目，苦參堿類新型HSP90抑制劑的設計合成及其抗非酒精性脂肪性肝炎（NASH）應用研究，主持

6）國家自然科學基金重點項目，能量代謝調控新靶點、新機制發現與創新藥物研究，第一參與人

6. 代表性成果

2022年SCI文章

1) Qian Zhou, Meiling Le, Yiyi Yang, Wenjuan Wang, Yuqi Huang, Quan Wang, Yijing Tian, Meiyan Jiang, Yong Rao*, Hai-Bin Luo*, Yinuo Wu*. Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: suppression of neuroinflammation by blocking NF-kB transcription regulation and activating cAMP/CREB axis. Acta Pharmaceutica Sinica B, 2022. https://doi.org/10.1016/j.apsb.2022.09.023 (共同通訊作者，IF 14.903)

2) Chan Li, Yao-Hao Xu, Yu-Tao Hu, Xiu Zhou, Zhi-Shu Huang, Ji-Ming Ye, Yong Rao*. Matrine counteracts obesity in mice via inducing adipose thermogenesis by activating HSF1/PGC-1α axis. Pharmacologic Res, 2022, 177: 106316. (通訊作者，IF 10.334)

3) Yong Rao*, Chan Li, Yu-Tao Hu, Yao-Hao Xu, Bing-Bing Song, Shi-Yao Guo, Zhi Jiang, Dan-Dan Zhao, Shuo-Bin Chen, Jia-Heng Tan, Shi-Liang Huang, Qing-Jiang Li, Xiao-Jun Wang, Ying-Jun Zhang, Ji-Ming Ye, Zhi-Shu Huang*. A novel HSF1 activator ameliorates non-alcoholic steatohepatitis by stimulating mitochondrial adaptive oxidation. Br J Pharmacol, 2022, 179, 1411-1432. (第一作者/共同通訊作者，IF 9.473)

4) Yong Rao*, Chan Li, Yao-Hao Xu, Yu-Tao Hu, Xiu Zhou, Darren C Henstridge, Zhi-Shu Huang*, Ji-Ming Ye*. Activation of HSP72/PRDX6 axis by matrine enhances mitophagy to protect against MAFLD in mice. Br J Pharmacol, 2022. (2^nd修訂，第一作者/共同通訊作者，IF 9.473)

5) Wen-Di Duan, Jing-Yu Cao, Chao-Yun Cai, Zhi-Rong Yang, Jin-Feng Cui, Tian Lan, You-Nan Chen, Jing Wang, Yong Rao*, Zhi-Shu Huang, Bo Wang*. Xanthone sulfonamide derivatives-A novel series of α-glucosidase inhibitors with different inhibitory types. J Mol Structure, 2022, 1263, 133026. (共同通訊作者，IF 3.841)

6) Xin-Chen Jiang, Fang-Hai Tu, Li-Yuan Wei, Bo-Zheng Wang, Hao Yuan, Jing-Mei Yuan, Yong Rao, Shi-Liang Huang, Qing-Jiang Li, Tian-Miao Ou, Hong-Gen Wang, Jia-Heng Tan, Shuo-Bin Chen*, Zhi-Shu Huang*. Discovery of a Novel G‑Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer. J Med Chem, 2022, 65(18), 12346-12366. (IF 8.039)

7) Fulin Jiang, Juntao Zheng, Yong Rao, Chang Zhang, Zhishu Huang, Min Huang, Guoping Zhong. Determination of IQZ23 in rat plasma using LC-MS/MS: consideration for matrix effect and internal standard interference. Bioanalysis, 2022, 14, 455-465. (IF 2.695)

8) Xin Pan, Teng-yu Mao, Yan-wen Mai, Cheng-cheng Liang, Wei-hao Huang, Yong Rao, Zhi-shu Huang, Shi-liang Huang*. Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy. Molecules, 2022, 27, 561 (IF 4.927)

9) Xue-Long Yan; Yue-Hua Pan; Run-Zhu Fan; Qin-Qin Song; Shen Li; Jia-Luo Huang; Wei Li; Dong Huang; Fang-Yu Yuan; Gui-Hua Tang; Yong Rao*; Zhi-Shu Huang, Shen Yin*. Discovery of the first Raptor (regulatory-associated protein of mTOR) Inhibitor as a New Type of Antiadipogenic Agent. Metabolism. (Under review, 共同通訊作者，IF13.9)

10) Yong Rao*, Rui Su, Xing-Xing Chai, Jin-Jian Li, Chen-Yan Wu, Guan-Yu Yang, Jun-Jie Wu, Zhong-Ping Jiang, Zhi-Kai Guo, Cong-Jun Xu*, Ling Huang*. Pharmacologic inhibition of PLA2/IRE-1α/XBP-1s axis and JNK signaling by marine fungus Aspergillus sp. c1 metabolite prevents MAFLD in mice. Br J Pharmacol, 2022. (第一作者/共同通訊作者，Under review, IF 9.473)

2021年SCI文章

1) Yong Rao^{1, *}, Zhiqi Kuang, ChaN Li, Shiyao Guo, Yaohao Xu, Dandan Zhao, Yutao Hu, Bingbing Song, Zhi Jiang, Zhenhuang Ge, Xiyuan Liu, Chengdao Li, Shuobin Chen, Jiming Ye, Zhishu Huang^*, Yongjun Lu^*. Gut Akkermansia muciniphila ameliorates metabolic dysfunction associated fatty liver disease by regulating the metabolism of L-aspartate via gut liver axis. Gut Microbes. 2021, 13, 1-19. (第一作者/共同通訊作者，IF 10.245)

2020年SCI文章

1) Yong Rao^1，*, Zhao Xu¹, Yu-Tao Hu, Chan Li, Yao-Hao Xu, Qin-Qin Song, et al. Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders. Eur J Med Chem, 2020, 192, 112172. (第一作者/共同通訊作者，IF 6.514)

2) Chen-Xi Wang, Zi-Lin Zhang, Qi-Kun Yin, Jia-Li Tu, Jia-En Wang, Yao-Hao Xu, Yong Rao, et al. Design, Synthesis, and Evaluation of NewQuinazolinone Derivatives that Inhibit Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors. J Med Chem, 2020, 63, 9752-9772. (IF 7.446)

2019年SCI文章

1) Yong Rao^*, Yu-Ting Lu, Chan Li, Qin‐Qin Song, Yao‐Hao Xu, Zhao Xu, Yu‐Tao Hu, Hong Yu, Lin Gao, Lian‐Quan Gu, Ji‐Ming Ye^*, Zhi‐Shu Huang^*. Bouchardatine analogue alleviates non‐alcoholic hepatic fatty liver disease/non‐alcoholic steatohepatitis in high‐fat fed mice by inhibiting ATP synthase activity. Br J Pharmacol, 2019, 176, 2877-2893. (第一作者/共同通訊作者，IF 8.739)

2) Qin-Qin Song¹, Yong Rao¹, Gui-Hua Tang¹, Zhang-Hua Sun, Jun-Sheng Zhang, Zhi-Shu Huang^*, Sheng Yin^*. Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes. J Med Chem, 2019, 2060-2075. (共同通訊作者，IF 7.446)

3) Yao-Hao Xu, Qin-Qin Song, Chan Li, Yu-Tao Hu, Bing-Bing Song, Ji-Ming Ye, Yong Rao∗, Zhi-Shu Huang. Bouchardatine suppresses rectal cancer in mice by disrupting its metabolic pathways via activating the SIRT1-PGC-1α-UCP2 axis. Eur J Pharmacol, 2019, 854, 328-337. (共同通訊作者，IF 4.432)

4) Wei Li, Ya-Qi Tang, Shi-Xin Chen, Gui-Hua Tang, Li-She Gan, Chan Li, Yong Rao, Zhi-Shu Huang, and Sheng Yin. Euphorhelipanes A and B, Triglyceride-Lowering Euphorbia Diterpenoids with a Bicyclo[4.3.0]nonane Core from Euphorbia helioscopia. J Nat Prod, 2019, 82, 412-416. (IF 4.05)

5) Yao-Hao Xu, Wei Li, Yong Rao*, Zhi-Shu Huang, Sheng Yin *. Pyridocarbazole alkaloids from Ochrosia borbonica: lipid-lowering agents inhibit the cell proliferation and adipogenesis of 3T3-L1 adipocyte via intercalating into supercoiled DNA. Chin J Nat Med, 2019, 17, 663-671. (共同通訊作者，IF 3.0)

2019年之前發表SCI文章

1) Lin Gao, Zhao Xu, Yong Rao*, Yu-Ting Lu, Yu-Tao Hu, Hong Yu, Yao-Hao Xu, et al. Design, synthesis and biological evaluation of novel bouchardatine analogs as potential inhibitors of adipogenesis/lipogenesis in 3T3-L1 adipocytes. Eur J Med Chem., 2018, 147, 90-101. (共同通訊作者，IF6.514)

2) Chao-Yun Cai, Li Rao, Yong Rao, Jin-Xuan Guo, Zhi-Zun Xiao, Jing-Yu Cao, Zhi-Shu Huang, Bo Wang. Analogues of xanthones Chalcones and bis-chalcones as aglucosidase inhibitors and anti-diabetes candidates. Eur J Med Chem., 2018, 147, 90-101. (IF 6.514)

3) Yong Rao, Hong Yu, Lin Gao, Yu-Ting Lu, Zhao Xu, Hong Liu, Lian-Quan Gu, Ji-Ming Ye^*, Zhi-Shu Huang^*. Natural alkaloid bouchardatine ameliorates metabolic disorders in high-fat diet-fed mice by stimulating the sirtuin 1/liver kinase B-1/AMPK axis. Br J Pharmacol., 2017, 174, 2457-2470. (第一作者，IF8.739)

4) Yong Rao¹, Hong Liu¹, Lin Gao, Hong Yu, Tian-Miao Ou, Jia-Heng Tan, Shi-Liang Huang, et al. Synthesis and Biological Evaluation of Novel Bouchardatine Derivatives as Potential Adipogenesis/Lipogenesis Inhibitors for Antiobesity Treatment. J Med Chem., 2015, 58, 9395-9413. 共同第一作者（排第一），IF7.446

5) Yong Rao, Hong Liu, Lin Gao, Hong Yu, Jia-Heng Tan, Tian-Miao Ou, Shi-Liang Huang, Lian-Quan Gu, Ji-Ming Ye, Zhi-Shu Huang. Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes. Bioorg Med Chem., 2015, 23, 4719-4727. (第一作者，IF3.641)

7.榮譽獎勵

2021年8月以海南省高層次人才引進進入365英国上市官网在线。

       歡迎對科研滿懷熱情的藥學、生物學、基礎醫學相關人才加入。